肿瘤细胞治疗研究
英文原题：The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors.
CD19.CAR-T 细胞在急性淋巴细胞白血病中的完全缓解率已超过 90%，在非霍奇金淋巴瘤中超过 60%。
CAR-T（CAR-T）细胞疗法作为过继免疫疗法，在恶性肿瘤治疗中的作用日益重要。CAR-T细胞被称为“活体药物”，因为它们不仅直接靶向肿瘤细胞，还能诱导长期免疫记忆，有望提供持久保护。CD19.CAR-T治疗急性淋巴细胞白血病的完全应答率超过90%，治疗非霍奇金淋巴瘤超过60%。然而，CAR-T治疗实体瘤的应答率仍极低，且可能引起严重副作用。本文综述实体瘤微环境对CAR-T应用造成的限制，以及为应对这些限制而开发的解决方案，以期CAR-T治疗实体瘤未来能够达到目前临床治疗血液系统恶性肿瘤时所见的成功率。
Chimeric antigen receptor T (CAR-T) cell therapy, as an adoptive immunotherapy, is playing an increasingly important role in the treatment of malignant tumors. CAR-T cells are referred to as "living drugs" as they not only target tumor cells directly, but also induce long-term immune memory that has the potential to provide long-lasting protection. CD19.CAR-T cells have achieved complete response rates of over 90 % for acute lymphoblastic leukemia and over 60 % for non-Hodgkin's lymphoma. However, the response rate of CAR-T cells in the treatment of solid tumors remains extremely low and the side effects potentially severe. In this review, we discuss the limitations that the solid tumor microenvironment poses for CAR-T application and the solutions that are being developed to address these limitations, in the hope that in the near future, CAR-T cell therapy for solid tumors can attain the same success rates as are now being seen clinically for hematological malignancies.
MEMBER ACCOUNT
登录成功会直接打开下一页。
